1,017 reports of this reaction
3.7% of all ACLIDINIUM BROMIDE reports
#3 most reported adverse reaction
DRUG DOSE OMISSION is the #3 most commonly reported adverse reaction for ACLIDINIUM BROMIDE, manufactured by Covis Pharma US, Inc. There are 1,017 FDA adverse event reports linking ACLIDINIUM BROMIDE to DRUG DOSE OMISSION. This represents approximately 3.7% of all 27,417 adverse event reports for this drug.
Patients taking ACLIDINIUM BROMIDE who experience drug dose omission should discuss this symptom with their healthcare provider to determine whether it may be related to their medication and what alternatives may be available.
DRUG DOSE OMISSION is moderately reported among ACLIDINIUM BROMIDE users, representing a notable but not dominant share of adverse events.
In addition to drug dose omission, the following adverse reactions have been reported for ACLIDINIUM BROMIDE:
The following drugs have also been linked to drug dose omission in FDA adverse event reports:
DRUG DOSE OMISSION has been reported as an adverse event in 1,017 FDA reports for ACLIDINIUM BROMIDE. This does not prove causation, but indicates an association observed in post-market surveillance data.
DRUG DOSE OMISSION accounts for approximately 3.7% of all adverse event reports for ACLIDINIUM BROMIDE, making it one of the most commonly reported side effect.
If you experience drug dose omission while taking ACLIDINIUM BROMIDE, contact your healthcare provider. They can evaluate whether the symptom is related to your medication and discuss potential adjustments to your treatment plan. Do not stop taking prescribed medication without consulting your doctor.